Weilun Lo

Array ( [id] => 17769392 [patent_doc_number] => 11401320 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => QTY FC fusion receptor proteins [patent_app_type] => utility [patent_app_number] => 17/210878 [patent_app_country] => US [patent_app_date] => 2021-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 13521 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17210878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946557 [patent_doc_number] => 20210205248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES [patent_app_type] => utility [patent_app_number] => 17/208064 [patent_app_country] => US [patent_app_date] => 2021-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17208064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717886 [patent_doc_number] => 11795217 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Interleukin-1 inhibition for combination treatment of pancreatic cancer cachexia [patent_app_type] => utility [patent_app_number] => 17/207272 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 16621 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17207272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18333923 [patent_doc_number] => 20230125871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS [patent_app_type] => utility [patent_app_number] => 17/912398 [patent_app_country] => US [patent_app_date] => 2021-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17912398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18683922 [patent_doc_number] => 11779632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => IL-2 muteins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/201350 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 16447 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17201350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468835 [patent_doc_number] => 20230203117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => IL-10 MUTEINS [patent_app_type] => utility [patent_app_number] => 17/910720 [patent_app_country] => US [patent_app_date] => 2021-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214550 [patent_doc_number] => 20210347887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 17/196451 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18362240 [patent_doc_number] => 20230143831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => ANTIGEN-PRESENTING EXTRACELLULAR VESICLES, COMPOSITION CONTAINING SAME, AND METHOD FOR PRODUCTION THEREOF [patent_app_type] => utility [patent_app_number] => 17/802794 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20479411 [patent_doc_number] => 12527875 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Methods for treating graft versus host disease [patent_app_type] => utility [patent_app_number] => 17/800827 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 19173 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18268378 [patent_doc_number] => 20230089620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => Anti-IL-2 Antibody, and Antigen-Binding Fragment Thereof and Medical Use Thereof [patent_app_type] => utility [patent_app_number] => 17/904517 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18252111 [patent_doc_number] => 20230079150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER [patent_app_type] => utility [patent_app_number] => 17/799627 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18748384 [patent_doc_number] => 11807680 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Gremlin-1 crystal structure and inhibitory antibody [patent_app_type] => utility [patent_app_number] => 17/172109 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 16 [patent_no_of_words] => 18257 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17421287 [patent_doc_number] => 11254729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => IL-7R-a binding compounds [patent_app_type] => utility [patent_app_number] => 17/166441 [patent_app_country] => US [patent_app_date] => 2021-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 67829 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556081 [patent_doc_number] => 11312757 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Fusion protein comprising IL13 [patent_app_type] => utility [patent_app_number] => 17/158785 [patent_app_country] => US [patent_app_date] => 2021-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 21 [patent_no_of_words] => 49403 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17158785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977640 [patent_doc_number] => 20210221877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/151860 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17151860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18784830 [patent_doc_number] => 20230372483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/796349 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995934 [patent_doc_number] => 11912761 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => IL-1b neutralizing human monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 17/150689 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 17 [patent_no_of_words] => 10129 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18504666 [patent_doc_number] => 11702471 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => IL-1b neutralizing human monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 17/150691 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 17 [patent_no_of_words] => 10134 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156167 [patent_doc_number] => 20210317218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/150789 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18298876 [patent_doc_number] => 20230108562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => NOVEL MASKED CYTOKINES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/787741 [patent_app_country] => US [patent_app_date] => 2021-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17787741 [rel_patent_id] =>[rel_patent_doc_number] =>)